Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Carcinoma, Renal Cell 144Carcinoma, Non-Small-Cell Lung 51Carcinoma, Transitional Cell 50Melanoma 46Urinary Bladder Neoplasms 42Prostatic Neoplasms 32Kidney Neoplasms 29Neoplasm Metastasis 27Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Hepatocellular 20Triple Negative Breast Neoplasms 15Neoplasms 15Stomach Neoplasms 14Ovarian Neoplasms 14Clear-cell metastatic renal cell carcinoma 14Lung Neoplasms 13Uterine Cervical Neoplasms 12Carcinoma, Merkel Cell 11Small Cell Lung Carcinoma 9Pancreatic Neoplasms 9Head and Neck Neoplasms 8Esophageal Neoplasms 7Breast Neoplasms 7Urethral Neoplasms 6Endometrial Neoplasms 6Cholangiocarcinoma 6Urogenital Neoplasms 5Skin Neoplasms 5Recurrence 5

Interventions

tivozanib 1grapiprant 1Tamsulosin 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Palliative Care 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1Lycopene 1Gemcitabine 1Epirubicin 1Cystectomy 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Nivolumab × Genitourinary × Clear all
NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡